OpenCell Technologies Overview

  • Founded
  • 2008
Founded
  • Status
  • Private
  • Employees
  • 3
Employees
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $2.96M
Latest Deal Amount
  • Investors
  • 6

OpenCell Technologies General Information

Description

Developer of a cell and gene therapy platform designed to commercialize cell-based analysis techniques and discover new cancer therapies. The company's platform provides efficient, high-throughput and scalable transfection tools to the Life Science Industry, enabling researchers to use difficult to transect cells like primary and cancer stem cell cultures and discover new therapeutic cell-based therapies.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
  • CORTEX BioScience District, 4340 Duncan Avenue
  • BioGenerator, Suite 218
  • Saint Louis, MO 63110
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

OpenCell Technologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Grant 01-Jan-2019 $2.96M 00000 Completed Generating Revenue
3. Early Stage VC (Series A) 16-Mar-2015 00000 00000 00.000 Completed Generating Revenue
2. Accelerator/Incubator Completed Startup
1. Accelerator/Incubator Completed Startup
To view OpenCell Technologies’s complete valuation and funding history, request access »

OpenCell Technologies Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000 00.000000 00.00 00.00 00 00.00 00.000
To view OpenCell Technologies’s complete cap table history, request access »

OpenCell Technologies Patents

OpenCell Technologies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-9725709-B2 Intracellular delivery and transfection methods and devices Active 12-Mar-2013 000000000 0
US-20140273229-A1 Intracellular delivery and transfection methods and devices Granted 12-Mar-2013 000000000 0
US-20170292106-A1 Intracellular delivery and transfection methods and devices Pending 12-Mar-2013 000000000 0
US-20190055509-A1 Intracellular delivery and transfection methods and devices Abandoned 12-Mar-2013 C12M35/04 0

OpenCell Technologies Executive Team (6)

Name Title Board Seat Contact Info
Andrei Fedorov Ph.D Co-Founder & President
Levent Degertekin Ph.D Co-Founder
Mark Meacham Ph.D Co-Founder
Chad Stiening Chairman
Paul Olivo Ph.D Advisor
You’re viewing 5 of 6 executive team members. Get the full list »

OpenCell Technologies Board Members (2)

Name Representing Role Since
Chad Stiening OpenCell Technologies Chairman 000 0000
Charles Bolten Self Board Member 000 0000
To view OpenCell Technologies’s complete board members history, request access »

OpenCell Technologies Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

OpenCell Technologies Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
National Institutes of Health Government 000 0000 000000 0
National Science Foundation Government 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
BioGenerator Venture Capital Minority 000 0000 000000 0
Synchrony Bio Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »